MSMohamed N. Sharafeldin

Mohamed N. Sharafeldin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mohamed N. Sharafeldin has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Nano-antioxidants for neurodegenerative disorders: a scoping review

    by Muhammad Talaat, Hamsa Hassan, Ethar Ahmed Mosilhy, Nouran A. Taha, Mohamed Elsaid, Mohamed N. Sharafeldin, Youssef K. Ghallab, Mostafa A. Lotfy, Mohab Ali Abdelqawy, Amira Ayman Ahmed, et al.

    Antioxidants showed usefulness in treating or preventing neurodegenerative diseases (NDDs). However, antioxidants have limited bioavailability owing to the


  • Lipid-Based Nanocarriers for Brain Delivery of Bioactives in the Treatment of Neurodegenerative Disorders

    by Khaled M. Kotb, Mohamed N. Sharafeldin, Hamsa Hassan, Achouak Boutalbi, Ahmed Yahya, Haseen Fatima Niazi, Nouran A. Taha, Islam Omar, Amgad E. Salem

    Neurodegenerative diseases include diverse conditions (e.g., Parkinson’s disease and Alzheimer’s disease) in which ongoing loss of neurons and glial cells is implicated. They lead to impaired motor and cognitive functions. Although there is an advancement in therapeutic options impacting the pathogenetic mechanisms of the disease, the BBB exerts a physiological barrier that hinders their access to the brain. Thereby, novel drug delivery approaches have been considered to enhance CNS targeting and bioavailability. There is increasing evidence that lipid-based nanocarriers (e.g., liposomes) may improve brain targeting and ease BBB transportation. Nevertheless, no authorized nanoformula targets the CNS till now. We aim to summarize the relevant literature about the different types of lipid-based nanocarriers and the findings of the preclinical and clinical trials conducted so far through systematic and manual searches in PubMed. Hence, it may be inspiring to translate this approach into clinical practice and benefit from their pharmacokinetic characteristics. Moreover, we attempt to highlight the challenges and future outlooks for their implementation in clinical practice. Overall, it is still early for these applications to be translated into clinical practice due to several reasons, including safety concerns; the lack of simple formulas that can be eligible and allow affordable, large-scale production; and the absence of reliable, high-quality, and strong evidence. We suggest that there is a necessity for appropriately designed controlled trials and standardized analytical methods.